Defining antimicrobial susceptibility testing methods and breakpoints among Achromobacter species
Open Access
- 11 June 2025
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (6) , e0026425
Abstract
Achromobacter species can cause opportunistic infections which are difficult to treat due to a variety of antimicrobial resistance (AMR) mechanisms. As such, antimicrobial susceptibility testing (AST) is a cornerstone to successful treatment for these organisms. Currently, there are no specific Clinical and Laboratory Standards Institute (CLSI) AST guidelines for Achromobacter species. The purpose of this study was to (i) establish tentative CLSI M45 MIC and disk diffusion (DD) breakpoints (BPs), (ii) evaluate the modified carbapenem inactivation method (mCIM), and (iii) understand the mechanisms mediating AMR among Achromobacter species. Contemporary MIC data from multiple sources were collated to define the tentative epidemiological cutoff values (tECVs), and the MIC distributions were used to inform the establishment of MIC BPs for various agents. A disk-to-MIC correlate study with 91 isolates from across the United States was completed by testing reference broth microdilution and DD from the same inoculum and applying the dBETS software to establish DD BPs. Lastly, the mCIM and whole-genome sequencing (WGS) were pursued. The tECVs for piperacillin-tazobactam, imipenem, and meropenem were 1, 2, and 0.5 µg/mL, respectively. Disk correlates met CLSI M23 acceptance criteria with a few exceptions related to a small number of isolates, resulting in high minor errors. WGS revealed that 82 (90.1%) isolates harbored a bla OXA variant with bla OXA-114 predominating (90.2%). Nineteen isolates harbored acquired beta-lactamase genes, including 16 bla AXC , 2 bla VIM-4 , and 1 bla AZM-1. The mCIM had a sensitivity of 100% and specificity of 87%. Upon review, the CLSI M45 committee set tentative MIC and DD BPs for piperacillin-tazobactam, imipenem, meropenem, and trimethoprim-sulfamethoxazole. IMPORTANCE: Achromobacter species can cause opportunistic infections which may be difficult to treat due to a variety of antimicrobial resistance mechanisms. Antimicrobial susceptibility testing is a critical component of patient treatment for these infections. Currently, the Clinical and Laboratory Standards Institute M100 non-Enterobacterales susceptibility test interpretive criteria and methodology are utilized for Achromobacter by clinical laboratories and likely do not accurately predict susceptibility results for Achromobacter species. This study was designed to establish tentative MIC and disk diffusion breakpoints specific to Achromobacter species.Keywords
This publication has 20 references indexed in Scilit:
- Ultrafast one‐pass FASTQ data preprocessing, quality control, and deduplication using fastpiMeta, 2023
- GAMMA: a tool for the rapid identification, classification and annotation of translated gene matches from sequencing dataBioinformatics, 2021
- Development of a database for the rapid and accurate routine identification of Achromobacter species by matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF MS)Clinical Microbiology and Infection, 2021
- List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZInternational Journal of Systematic and Evolutionary Microbiology, 2020
- Achromobacter Infections and Treatment OptionsAntimicrobial Agents and Chemotherapy, 2020
- Expansion and improvement of MALDI-TOF MS databases for accurate identification of Achromobacter speciesJournal of Microbiological Methods, 2020
- Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidansScientific Reports, 2018
- SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell SequencingJournal of Computational Biology, 2012
- Characterization of a Naturally Occurring Class D β-Lactamase from Achromobacter xylosoxidansAntimicrobial Agents and Chemotherapy, 2008
- Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off valuesClinical Microbiology and Infection, 2006